Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
{{output}}
Humans possess abundant amounts of microorganisms, including bacteria, fungi, viruses, and archaea, in their gut. Patients with nonalcoholic fatty liver disease (NAFLD) exhibit alterations in their gut microbiome and an impaired gut barrier function. Preclinic... ...
